Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.

Chemotherapy has long been a cornerstone of cancer treatment, saving millions of lives. Drugmakers have poured billions of dollars into developing ADCs. The medicines are designed to deliver potent ...

SAN FRANCISCO -- Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease ...

Autoimmune diseases share the same core pathology despite their differing clinical manifestations: dysregulated B and T cell activity. B cells contribute to disease progression by secreting ...

Chemotherapy has long been a cornerstone of cancer treatment, saving millions of lives. Stream Los Angeles News for free, 24/7, wherever you are. Drugmakers have poured billions of dollars into ...